<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03656575</url>
  </required_header>
  <id_info>
    <org_study_id>17-01551</org_study_id>
    <nct_id>NCT03656575</nct_id>
  </id_info>
  <brief_title>Reduction of Pro-Inflammatory Synovial Fluid Biomarkers in Osteoarthritis of the Knee With Alpha-2 Macroglobulin</brief_title>
  <official_title>Reduction of Pro-Inflammatory Synovial Fluid Biomarkers in Osteoarthritis of the Knee With Alpha-2 Macroglobulin: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the current study is to assess the ability of alpha-2-macroglobulin treatment
      to reduce the level of pro-inflammatory synovial fluid biomarkers in patients with
      osteoarthritis of the knee.

      This is a double-blinded rationalized control trial with prospective data collection. The
      study will collect and analyze the synovial fluid, serum, and urine of patients presenting
      with knee osteoarthritis in Kellegren-Lawrence grade 2 or 3. It will compare synovial fluid
      biomarker levels between patients receiving an intra-articular alpha-macroglobulin,
      intra-articular PR injection and intra-articular corticosteroid serving as a control.
      Pre-injection pain and function will be assessed. Post-injection pain, function and outcomes
      will be assessed after six weeks and three months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">April 20, 2019</completion_date>
  <primary_completion_date type="Actual">April 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of synovial fluid biomarker levels</measure>
    <time_frame>6 Weeks</time_frame>
    <description>synovial fluid will be aspirated and analyzed for the presence of 20 biomarkers using bead assay (Milliplex®, Millipore, Billerica MA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of synovial fluid biomarker levels</measure>
    <time_frame>3 Months</time_frame>
    <description>synovial fluid will be aspirated and analyzed for the presence of 20 biomarkers using bead assay (Milliplex®, Millipore, Billerica MA)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>intra-articular alpha-2-macroglobulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intra-articular injection of 1 mL of the 40 mg/ml strength (1 vial)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intra-articular Platelet-rich Plasma (PRP) injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care PRP treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intra-articular corticosteroid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of Care steroid treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>synovial fluid biomarker concentrations</intervention_name>
    <description>Synovial fluid samples will be obtained pre-injection, Post Injection 3 Weeks, Post Injection 6 Weeks, Post Injection 9 Weeks, Post Injection 3 Months, Post Injection 6 Months, Post Injection phone call at 1 Year</description>
    <arm_group_label>Intra-articular corticosteroid</arm_group_label>
    <arm_group_label>intra-articular Platelet-rich Plasma (PRP) injection</arm_group_label>
    <arm_group_label>intra-articular alpha-2-macroglobulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients osteoarthritis classified as Kellegren-Lawrence grade 2 or 3

        Exclusion Criteria:

          -  Mentally impaired (e.g, Alzheimer's subjects, dementia, etc.)

          -  Younger than 18 years of age

          -  Greater than 90 years of age

          -  Patients with underlying inflammatory arthropathies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laith Jazrawi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

